Actively Recruiting
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
Led by Capital Medical University · Updated on 2026-03-23
384
Participants Needed
2
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.
CONDITIONS
Official Title
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients hospitalized at a participating medical institution.
- Patients or their legal guardians must agree to participate and sign informed consent.
- Index cases must be 2 years or older with confirmed influenza by Rapid Antigen Test or Nucleic Acid Amplification Test on respiratory samples.
- Room contacts must be 12 years or older.
- Room contacts must be expected to remain hospitalized for at least 72 hours.
- Room contacts must share a room with a confirmed influenza index case diagnosed within the last 120 hours who developed symptoms within the last 120 hours and will share the room for at least 24 hours.
- Room contacts must test negative for influenza by Nucleic Acid Amplification Test on a throat swab collected on Day 1.
You will not qualify if you...
- Room contacts with known allergy to the active ingredients or excipients of the study drugs.
- Room contacts diagnosed with or having had influenza infection in the past 12 weeks.
- Room contacts who used any anti-influenza antiviral drugs within 2 weeks before screening.
- Room contacts who are pregnant or breastfeeding.
- Room contacts with a fever of 37.3�b0C or higher within 72 hours before screening.
- Room contacts with Child-Pugh class B or C liver disease or an eGFR of 60 mL/min/1.73 m�b2/min or lower.
- Any subject judged unsuitable for the study by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
China-Japan Friendship hospital, Beijing, Beijing
Beijing, Beijing Municipality, China, 100029
Not Yet Recruiting
2
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Y
Yeming Wang, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here